Search Bar & Filters
Found 22 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.
Actively Recruiting
Researchers are evaluating zelquistinel, a drug aimed at reducing symptoms of major depressive disorder in adults aged 18 to 64 years. This Phase 2 clinical trial compares the effects and safety of zelquistinel to a placebo in participants diagnosed with major depressive disorder. The study will focus on changes in depression severity and monitor any medical issues that arise during treatment. Participants will take one tablet of either zelquistinel or placebo once a week for six weeks. The trial includes a screening period of up to 28 days, followed by a 42-day treatment phase, and then a four-week follow-up period. During treatment, participants will visit the clinic weekly to receive their dose and have their depression symptoms assessed using the Hamilton Depression Rating Scale-17. Throughout the study, participants will have their depression severity regularly evaluated, along with monitoring for adverse events or side effects. The study lasts up to 98 days, including screening, treatment, and follow-up. Researchers will measure changes in depression scores from the beginning to the end of treatment and monitor overall safety during this time.
Actively Recruiting
This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in adults with chronic kidney disease CKD Stage 3b and 4, who have an estimated glomerular filtration rate eGFR between 15 and less than 45 mLmin1.73 m2. This Phase III study focuses on a population with high unmet medical needs and increased risk of CKD progression, often excluded from other trials. The main goal is to see if the combination reduces cardiovascular death, kidney failure, and heart failure events. Participants will be randomly assigned to one of two groups one receiving a daily capsule containing balcinrenone 15 mg and dapagliflozin 10 mg plus a placebo tablet matching dapagliflozin, and the other receiving a dapagliflozin 10 mg tablet plus a placebo capsule matching balcinrenonedapagliflozin. All treatments are taken orally once daily alongside standard of care therapy. The study is conducted globally at approximately 550 sites in about 30 countries. During the study, participants will be monitored for up to 46 months to track outcomes such as cardiovascular death, kidney failure, and decline in kidney function measured by eGFR. Researchers will also assess changes in urinary albumin to creatinine ratio and overall safety and tolerability. Participants will have regular visits for assessments including laboratory tests and clinical evaluations to measure these outcomes and monitor health status throughout the study.
Actively Recruiting
Researchers are evaluating the drug efruxifermin EFX in adults with compensated cirrhosis caused by NASH Nonalcoholic Steatohepatitis or MASH Metabolic Dysfunction-Associated Steatohepatitis. This phase 3, randomized, double-blind, placebo-controlled study aims to assess the safety and efficacy of EFX in slowing disease progression and improving liver health over several years. Participants will be randomly assigned to receive either EFX 50 mg or a placebo, both given by subcutaneous injection. The study includes two cohorts one with biopsy-proven compensated cirrhosis and metabolic features, and another diagnosed either by biopsy or non-invasive methods. Treatment and follow-up will continue for up to five years to monitor outcomes. Throughout the study, participants will undergo regular assessments including liver fibrosis markers, liver injury markers, lipoproteins, insulin sensitivity, glycemic control, and body weight changes. Safety will be closely monitored through laboratory tests, ECGs, ultrasounds, and vital signs. The primary outcome measures include time to significant clinical events like disease progression or liver decompensation and improvements in fibrosis and steatohepatitis, with follow-up extending up to five years.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of efruxifermin EFX in adults with non-cirrhotic nonalcoholic steatohepatitis NASH or metabolic dysfunction-associated steatohepatitis MASH who have moderate to advanced liver fibrosis stage 2 or 3. This Phase 3, multi-center study randomly assigns participants to different treatment groups and compares EFX with a placebo to see its impact on liver health and related clinical outcomes. Participants are divided into two groups one with about 750 subjects having confirmed NASHMASH and fibrosis stage 2 or 3, and another with about 900 subjects with fibrosis stage 3 regardless of their NAFLD activity score. They receive either 28 mg or 50 mg of EFX or a matching placebo through weekly injections under the skin. The study includes a screening period up to 12 weeks, a 52-week treatment phase for the first group, a 96-week phase for the second group, and an extended follow-up period lasting up to around 240 weeks, plus a follow-up visit about a month after the last dose. During the study, participants undergo liver biopsies, blood tests, imaging scans like FibroScan, and assessments of liver fibrosis markers and metabolism-related measures. Researchers monitor changes in liver tissue, liver function tests, cholesterol, blood sugar control, body weight, and safety indicators over time. Even if participants stop the study drug early, they may continue with scheduled assessments to support long-term evaluation of treatment effects and safety throughout the study duration.
Actively Recruiting
Immunoglobulin A nephropathy IgAN is a kidney disease where immune system proteins build up in the kidneys causing inflammation. This inflammation may lead to kidney damage over time and reduce kidney function. The study is evaluating how well mezagitamab changes protein levels in the urine compared to a placebo in adults with primary IgAN. It also aims to assess the safety and tolerability of mezagitamab and how it maintains kidney function long term compared to placebo. Participants are randomly assigned to one of two groups in the main study two-thirds will receive mezagitamab injections and one-third will receive placebo injections, both given subcutaneously for about 22 weeks. Additionally, an open-label group includes participants with varying protein levels or kidney function who receive mezagitamab similarly. The entire study lasts about 2 years, with treatment for 22 weeks followed by approximately 1.5 years of observation. During the study, participants will have regular clinic visits, including monthly check-ups during the observation period. Assessments include measuring changes in urine protein levels and kidney function over time. Safety and tolerability of the study drug will also be monitored throughout the trial. Participants may continue in the study for up to 104 weeks, with ongoing evaluations to track kidney health and proteinuria.
Actively Recruiting
Major depressive disorder MDD is a mood disorder causing ongoing sadness and loss of interest, with emotional and physical symptoms such as irritability, difficulty focusing, tiredness, and changes in eating habits. Researchers are studying oral Icalcaprant, an investigational drug, to assess its effects on disease activity and side effects in adults currently experiencing a major depressive episode. Participants are randomly assigned to one of three groups two different doses of Icalcaprant or a placebo. They will take oral capsules once daily for 6 weeks, followed by a 30-day safety follow-up period. The study is conducted at about 35 sites across North America and involves approximately 195 adults. During the study, participants will attend regular visits at a hospital or clinic where medical assessments, blood tests, side effect checks, and questionnaires will be completed. Researchers will measure changes in depression severity using scales like the Montgomery-sberg Depression Rating Scale MADRS over about 6 weeks, and adverse events will be monitored for up to 10 weeks total.
Actively Recruiting
Researchers are evaluating the effects of a medicine called BI 764198 in adults and adolescents with a kidney disease known as focal segmental glomerulosclerosis FSGS. This Phase 3 study aims to understand whether BI 764198 can help people with primary FSGS or genetic FSGS related to TRPC6 gene mutations. The trial is randomized, double-blind, and placebo-controlled, comparing BI 764198 tablets to placebo tablets. Participants take one tablet daily for up to two years alongside their usual FSGS treatments. They are randomly assigned to either the BI 764198 group or the placebo group, with equal chance to be in either. The study monitors participants over 104 weeks, collecting urine samples regularly to assess kidney function and compare results between groups. During the study, participants visit the study site about every three months for health assessments and safety monitoring. Researchers measure changes in urine protein-creatinine ratio and kidney filtration rate to evaluate treatment response. Additional questionnaires assess disease impact. The total participation time is up to two years, allowing long-term evaluation of the treatments effects and safety.
Actively Recruiting
Researchers are evaluating the cardiovascular outcomes of elecoglipron compared with a placebo in adults with heart failure with preserved ejection fraction HFpEF or mildly reduced ejection fraction HFmrEF. This Phase III, randomized, double-blind, placebo-controlled study includes participants regardless of type 2 diabetes status who are also taking dapagliflozin along with other standard care treatments. Participants are randomly assigned to receive either elecoglipron tablets once daily or matching placebo tablets once daily. The study is conducted across multiple centers and follows a parallel-group design. The treatment period may last up to 42 months, during which the effects of elecoglipron on cardiovascular events and patient outcomes are assessed. Throughout the study, participants undergo regular evaluations to monitor their heart failure status, including assessments of cardiovascular death risk, hospitalization for heart failure, and urgent heart failure visits. Patient-reported outcomes are collected using questionnaires at baseline and at 52 weeks. Safety and efficacy are closely monitored over the extended treatment period to determine the impact of elecoglipron compared to placebo.
1-10 of 22
1